COVID-19 disease and autoimmune disorders: A mutual pathway
- PMID: 36159097
- PMCID: PMC9350728
- DOI: 10.5662/wjm.v12.i4.200
COVID-19 disease and autoimmune disorders: A mutual pathway
Abstract
Coronavirus disease 2019 (COVID-19) is a real challenge for humanity with high morbidity and mortality. Despite being primarily a respiratory illness, COVID-19 can affect nearly every human body tissue, causing many diseases. After viral infection, the immune system can recognize the viral antigens presented by the immune cells. This immune response is usually controlled and terminated once the infection is aborted. Nevertheless, in some patients, the immune reaction becomes out of control with the development of autoimmune diseases. Several human tissue antigens showed a strong response with antibodies directed against many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins, such as SARS-CoV-2 S, N, and autoimmune target proteins. The immunogenic effects of SARS-CoV-2 are due to the sizeable viral RNA molecules with interrupted transcription increasing the pool of epitopes with increased chances of molecular mimicry and interaction with the host immune system, the overlap between some viral and human peptides, the viral induced-tissue damage, and the robust and complex binding between sACE-2 and SARS-CoV-2 S protein. Consequently, COVID-19 and its vaccine may trigger the development of many autoimmune diseases in a predisposed patient. This review discusses the mutual relation between COVID-19 and autoimmune diseases, their interactive effects on each other, the role of the COVID-19 vaccine in triggering autoimmune diseases, the factors affecting the severity of COVID-19 in patients suffering from autoimmune diseases, and the different ways to minimize the risk of COVID-19 in patients with autoimmune diseases.
Keywords: Autoimmune Diseases; COVID-19; SARS-CoV-2; Vaccines.
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
Similar articles
-
Autoimmune liver diseases and SARS-CoV-2.World J Gastroenterol. 2023 Mar 28;29(12):1838-1851. doi: 10.3748/wjg.v29.i12.1838. World J Gastroenterol. 2023. PMID: 37032727 Free PMC article. Review.
-
Using bioinformatic protein sequence similarity to investigate if SARS CoV-2 infection could cause an ocular autoimmune inflammatory reactions?Exp Eye Res. 2021 Feb;203:108433. doi: 10.1016/j.exer.2020.108433. Epub 2021 Jan 2. Exp Eye Res. 2021. PMID: 33400927 Free PMC article.
-
Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients.J Transl Med. 2023 Feb 14;21(1):123. doi: 10.1186/s12967-023-03963-5. J Transl Med. 2023. PMID: 36788606 Free PMC article.
-
Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.Front Immunol. 2020 Aug 7;11:1949. doi: 10.3389/fimmu.2020.01949. eCollection 2020. Front Immunol. 2020. PMID: 32849654 Free PMC article. Review.
-
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949. Cells. 2021. PMID: 34831172 Free PMC article. Review.
Cited by
-
The Onset of Antinuclear Antibodies (ANAs) as a Potential Risk Factor for Mortality and Morbidity in COVID-19 Patients: A Single-Center Retrospective Study.Biomedicines. 2024 Jun 13;12(6):1306. doi: 10.3390/biomedicines12061306. Biomedicines. 2024. PMID: 38927513 Free PMC article.
-
COVID-19 and antiphospholipid antibodies.Best Pract Res Clin Haematol. 2022 Sep;35(3):101402. doi: 10.1016/j.beha.2022.101402. Epub 2022 Oct 15. Best Pract Res Clin Haematol. 2022. PMID: 36494152 Free PMC article. Review.
-
Pre- and Post- COVID-19 Pandemic Pneumonia Rates in Hospitalized Schizophrenia Patients.Medicina (Kaunas). 2025 Jul 10;61(7):1251. doi: 10.3390/medicina61071251. Medicina (Kaunas). 2025. PMID: 40731880 Free PMC article.
-
Angiotensin-Converting Enzyme-2 (ACE2) Downregulation During Coronavirus Infection.Mol Biotechnol. 2024 Sep 13. doi: 10.1007/s12033-024-01277-5. Online ahead of print. Mol Biotechnol. 2024. PMID: 39266903 Review.
-
COVID-19-induced gastrointestinal autonomic dysfunction: A systematic review.World J Clin Cases. 2023 Aug 6;11(22):5252-5272. doi: 10.12998/wjcc.v11.i22.5252. World J Clin Cases. 2023. PMID: 37621592 Free PMC article.
References
-
- Saeed NK, Al-Biltagi M, Bediwy AS. Molecular Testing for COVID-19: What the Clinician Should Know. Dr. Sulaiman Al Habib Medical Journal. 2021:53–59.
-
- Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. JAMA. 2020;323:707–708. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous